Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor

Seminars in Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2008, Pages 217-223

  Harichand Herdt, Seema ^a   Ramalingam, Suresh S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

cetuximab; EGFR; erlotinib; gefitinib; non small cell lung cancer

Indexed keywords

BIBW 2992; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; PEMETREXED; PF 00299804; PLACEBO; PLATINUM COMPLEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; XL 647;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 56349151873     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2008.09.005     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346 (2002) 92-98
3. Pirker R., Szczesna A., von Pawel J., et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 suppl (2008) 6S (abstract 3)
4. Shepherd F.A., Rodrigues Pereira J., et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353 (2005) 123-132
5. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 suppl 2 (2004) 21-26
6. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
7. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53 suppl 10 (1993) 2379-2385
8. Franklin W.A., Veve R., Hirsch F.R., et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29 1 suppl 4 (2002) 3-14
9. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001) 2958-2970
10. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
11. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small cell lung cancer. J Clin Oncol 25 (2007) 760-766
12. Jackman D., Lindeman N.I., Lucca J., et al. Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol 25 18 suppl (2007) 7591 (meeting abstracts)
13. Lilenbaum R., Axelrod R., Thomas S., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2. J Clin Oncol 26 (2008) 863-869
14. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). [corrected]. J Clin Oncol 21 (2003) 2237-2246
15. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
16. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicenter study (IRESSA Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
17. Douillard J.Y., Hirsh v., Mok T.S., et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 26 suppl (2008) 8001
18. West H.L., Franklin W.A., McCoy J., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24 (2006) 1807-1813
19. Miller V.A., Riely G.J., Zakowski M.F., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26 (2008) 1472-1478
20. Hanna N., Lilenbaum R., Ansari R., et al. Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer. J Clin Oncol 24 (2006) 5253-5258
21. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 (2007) 1545-1552
22. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
23. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
24. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
25. Lee J.S., Ignacio J., Yu C., et al. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 26 suppl (2008) 8031
26. Lynch T.J., Patel T., Dreisbach L., et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC): B3-03. J Thorac Oncol 8 suppl 4 (2007) S340-S341
27. Yang C., Shih J., Chao T., Tsai C., Yu C., Yang P., et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase II clinical trial. J Clin Oncol 26 (2008) 430S (May 20 suppl) (abstract 8026)
28. Janne P.A., Schellens J.H., Engelman J.A., et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 26 (2008) 430S (May 20 suppl) (abstract 8027)
29. Rizvi N.A., Kris M.G., Miller V.A., et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from Phase 2. J Clin Oncol 26 (2008) 437S (May 20 suppl) (abstract 8053)
30. Miller V.A., Wakelee H.A., Lara P.N., et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. J Clin Oncol 26 (2008) 430S (May 20 suppl) (abstract 8028)
31. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
32. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. New Engl J Med 353 (2005) 133-144
33. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
34. Paz-Ares L., Sanchez J.M., García-Velasco A., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Journal of Clinical Oncology 24 suppl 18 (2006) 7020 2006 ASCO Annual Meeting Proceedings Part I. (June 20)
35. Jackman D.M., Yeap B.Y., Sequist L.V., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12 (2006) 3908-3914
36. Blumenschein G., Moughan J., Curran W., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): an interim report of the RTOG 0324 trial. J Clin Oncol 25 suppl 18 (2007) 392S (abstract 7531)